{"title":"FAM216A Promotes Hepatocellular Carcinoma Proliferation and Invasion through the PLK1/ERK Signaling Pathway.","authors":"Peng Ma, Ying Hao, Yuefeng Zhang, Weiguo Tang, Wei Wang, Zuo Muo, Kaihuan Yu, Weixing Wang","doi":"10.1177/19450265261417993","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Family with sequence similarity 216 member A (FAM216A) is overexpressed in several cancer tissues, but its prognostic value and pathological effect in hepatocellular carcinoma (HCC) have not been fully elucidated.</p><p><strong>Materials and methods: </strong>FAM216A expression in HCC specimens and cell lines was determined by real-time PCR and western blotting. FAM216A expression was knocked down in HCCLM3 and Huh7 cells, and overexpressed in Hep3B and PLC/PRF/5 cells. The proliferation, migration, and invasion of different HCC cell lines were assessed by colony formation and Transwell assays. The expression of epithelial-mesenchymal transition (EMT)-related proteins and the level of polo-like kinase 1/extracellular regulated protein kinase (PLK1/ERK) were determined.</p><p><strong>Results: </strong>Increased FAM216A expression was observed in HCC tissues, a result that is consistent with outcomes obtained from an online database, and patient prognosis was negatively correlated with the FAM216A expression level. Additionally, FAM216A overexpression promoted the proliferation, migration, and invasion of HCC cells and activated EMT via the PLK1/ERK signaling pathway.</p><p><strong>Conclusions: </strong>FAM216A is overexpressed in HCC tissues and is associated with poor clinical outcomes. Mechanistically, FAM216A promotes aggressive tumor behavior by activating the PLK1/ERK signaling pathway.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":" ","pages":"55-66"},"PeriodicalIF":1.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1177/19450265261417993","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: Family with sequence similarity 216 member A (FAM216A) is overexpressed in several cancer tissues, but its prognostic value and pathological effect in hepatocellular carcinoma (HCC) have not been fully elucidated.
Materials and methods: FAM216A expression in HCC specimens and cell lines was determined by real-time PCR and western blotting. FAM216A expression was knocked down in HCCLM3 and Huh7 cells, and overexpressed in Hep3B and PLC/PRF/5 cells. The proliferation, migration, and invasion of different HCC cell lines were assessed by colony formation and Transwell assays. The expression of epithelial-mesenchymal transition (EMT)-related proteins and the level of polo-like kinase 1/extracellular regulated protein kinase (PLK1/ERK) were determined.
Results: Increased FAM216A expression was observed in HCC tissues, a result that is consistent with outcomes obtained from an online database, and patient prognosis was negatively correlated with the FAM216A expression level. Additionally, FAM216A overexpression promoted the proliferation, migration, and invasion of HCC cells and activated EMT via the PLK1/ERK signaling pathway.
Conclusions: FAM216A is overexpressed in HCC tissues and is associated with poor clinical outcomes. Mechanistically, FAM216A promotes aggressive tumor behavior by activating the PLK1/ERK signaling pathway.
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling